[Newsmp] Pfizer's leukemia treatment Bosulif (ingredient: bosutinib), AstraZeneca's neurofibromatosis treatment Koselugo (ingredient: selumetinib), and Ono Pharma Korea's colorectal cancer treatment Braftovi (ingredient: encorafenib) will benefit from insurance coverage on the first day of the new year.
Ulcerative colitis drug Zeposia (ingredient: ozanimod) from BMS and respiratory treatment Trimbow (ingredient: beclometasone/formoterol/glycopyrrolate) from Kolon Pharmaceutical also have received the green light for insurance coverage.
The maximum reimbursement amount for existing items, such as the third-generation EGFR-TKI Tagrisso (ingredient: osimertinib) and Leclaza (ingredient: lazertinib), which have expanded the coverage to first-line treatment for non-small cell lung cancer, will be reduced.
However, the maximum benefits for anticonvulsants containing clonazepam, WhanIn Clonazepam Tab. 0.5mg (Whanin Pharmaceutical) and Rivotril Tab. (Chong Kun Dang Pharmaceutical), will be increased.
The Ministry of Health and Welfare issued a revision to the 'Pharmaceutical benefit list and the table of the upper limit of benefits' on December 22.
According to the revision, the maximum reimbursement amount for Zeposia Capsule 0.92mg is KRW 22,674 per capsule, and the reimbursement ceiling for Zeposia Starter Pack 0.23mg/0.46mg is KRW 81,628 per pack of 7 capsules.
Trimbow Pressurized inhalation 100/6/12.5 is set at KRW 46,669 per 120-dose inhaler, and Braftovi Cap. 75 mg at KRW 56,023 per capsule.
The maximum benefits of Bosulif 100mg tablets are KRW 22,552 per tablet, 400mg tablets at KRW 62,526, and 500mg tablets at KRW 76,550. Koselugo capsules are set at KRW 95,347 per 10mg capsule and KRW 235,464 per 25mg capsule.
Novartis' Jakavi (ingredient: ruxolitinib) in patients with myelofibrosis has been added with a 10mg dosage, and the maximum reimbursement amount is KRW 38,943.
Three existing products, Tagrisso 40mg and 80mg and Azabio 25mg (Pharmbio Korea), will have their maximum reimbursement amounts reduced by 10.0%, and Leclaza 80mg by 8.1%.
Everose (Samyang Holdings) will see its upper limit amount reduced by 5.0% for the 2.5mg and 5mg dosages, and by 4.6% for the 10mg dosage. Entresto film-coated Tab. (Novartis) will see its reimbursement ceilings decreased by 4.7% for all three dosages: 50mg, 100mg, and 200mg.
In contrast, the reimbursement ceiling for Lidocaine Injection 0.5% Samjin (Samjin Pharmaceutical) will increase by 287.6%, Children's Tylenol Suspension (Johnson & Johnson) by 55.6%, and Setopen Suspension (Sam-A Pharm.) by 52.9%.
Moreover, the maximum amount of benefits for Diazepam Inj. Samjin (Samjin Pharmaceutical) will advance by 44.5%, Samchundang Magnesium Oxide Tab. 250mg (SamChunDang Pharm) by 36.1%, WhanIn Lithium Carbonate Tab. (Whanin Pharmaceutical) by 27.6%, and WhanIn Clonazepam Tab. 0.5mg and Rivotril by 20.0%.
For Folic Acid Tab. Sinil (Sinil Pharmaceutical), Ditoren Fine Granule (Kukje Pharma), and Meiact Fine Granule Boryung (Boryung Pharmaceutical), their maximum reimbursement amounts will rise by 15.4%, 5.7%, and 0.9%, respectively.
